{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-23-000020","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2023-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.064548+00:00","generated_at":"2026-06-18T13:12:15.677768+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Keros Therapeutics reports Q4 2022 net loss of $29.7M; cash runway into Q3 2025","bullets":["Net loss of $29.7M for Q4 2022 vs $6.9M in Q4 2021; full year net loss $104.7M vs $58.7M.","No revenue in 2022; 2021 revenue of $20.1M from Hansoh license agreement.","R&D expenses $24.9M in Q4 2022, up from $18.8M; driven by Phase 2 trials of KER-050.","Cash and equivalents $279.0M at Dec 31, 2022; with ATM proceeds, funds operations into Q3 2025.","Anticipated 2023 milestones: complete MDS trial enrollment, report additional data for KER-050, KER-047, KER-012."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-23-000020","json":"https://secwatch.observer/filing/0001664710-23-000020.json","markdown":"https://secwatch.observer/filing/0001664710-23-000020.md","text":"https://secwatch.observer/filing/0001664710-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000020/0001664710-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000020/kros-20230303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T13:12:15.677768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f15d77b093131ef7ad4bb6749f2d254cc79b3f6","claim":"Keros Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income net loss of $29.7 million for the fourth quarter and $104.7 million for the year ended December 31, 2022.","evidence_excerpt":"Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000020/0001664710-23-000020-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Net income","value":"net loss of $29.7 million for the fourth quarter and $104.7 million for the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}